Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 25;10(3):550.
doi: 10.3390/biomedicines10030550.

Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role

Haripriya Gupta  1 , Byeong-Hyun Min  1 , Raja Ganesan  1 , Yoseph Asmelash Gebru  1 , Satya Priya Sharma  1 , Eunju Park  1 , Sung-Min Won  1 , Jin-Ju Jeong  1 , Su-Been Lee  1 , Min-Gi Cha  1 , Goo-Hyun Kwon  1 , Min-Kyo Jeong  1 , Ji-Ye Hyun  1 , Jung-A Eom  1 , Hee-Jin Park  1 , Sang-Jun Yoon  1 , Mi-Ran Choi  1 , Dong-Joon Kim  1 , Ki-Tae Suk  1
Affiliations
Review

Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role

Haripriya Gupta et al. Biomedicines. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) is considered to be a significant health threat globally, and has attracted growing concern in the research field of liver diseases. NAFLD comprises multifarious fatty degenerative disorders in the liver, including simple steatosis, steatohepatitis and fibrosis. The fundamental pathophysiology of NAFLD is complex and multifactor-driven. In addition to viruses, metabolic syndrome and alcohol, evidence has recently indicated that the microbiome is related to the development and progression of NAFLD. In this review, we summarize the possible microbiota-based therapeutic approaches and highlight the importance of establishing the diagnosis of NAFLD through the different spectra of the disease via the gut-liver axis.

Keywords: NAFLD; microbial functions; microbiota; microbiota-based approach.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Different mechanism involving gut microbiota in pathophysiology of non-alcoholic liver disease. Abbreviations: ↑ indicates an increase in the condition or level; ROS, reactive oxygen species; GSH, glutathione; Treg, regulatory T cells; IELs, intraepithelial lymphocytes; IgAs, immunoglobulin A; SCFAs, short-chain fatty acids; TMAO, trimethylamine N-oxide; AhR, aryl hydrocarbon receptor; FXR, farnesoid X receptor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ma X., Liu S., Zhang J., Dong M., Wang Y., Wang M., Xin Y. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: A systematic review and meta-analysis. BMC Gastroenterol. 2020;20:10. doi: 10.1186/s12876-020-1165-z. - DOI - PMC - PubMed
    1. Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M., George J., Bugianesi E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018;15:11–20. doi: 10.1038/nrgastro.2017.109. - DOI - PubMed
    1. Estes C., Razavi H., Loomba R., Younossi Z., Sanyal A.J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123–133. doi: 10.1002/hep.29466. - DOI - PMC - PubMed
    1. Sharma S.P., Suk K.T., Kim D.J. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J. Gastroenterol. 2021;27:6161–6179. doi: 10.3748/wjg.v27.i37.6161. - DOI - PMC - PubMed
    1. Adams L.A., Feldstein A.E. Nonalcoholic steatohepatitis: Risk factors and diagnosis. Expert Rev. Gastroenterol. Hepatol. 2010;4:623–635. doi: 10.1586/egh.10.56. - DOI - PubMed

LinkOut - more resources